Skip to main content
Fig. 1 | Clinical Epigenetics

Fig. 1

From: Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease

Fig. 1

The DNA methylation biomarker set differentiates between pancreatic adenocarcinoma and benign pancreatic disease with high sensitivity and specificity. A Mean DNA methylation signal per marker for the control group of 44 patients with benign pancreatic disease and for the group of 19 pancreatic ductal adenocarcinoma cases. The y-axis is in a log2 scale. p = 6.5 × 10–16 by Wilcoxon rank sum test. B The receiver operating characteristic (ROC) analysis of the biomarker set signal from 44 controls and 19 cancer cases. AUC area under the curve, CI confidence interval

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us